NEW YORK, December 29, 2025, 19:33 ET — After-hours
- Pfizer shares ticked lower in after-hours trading after a muted regular-session move.
- Thin year-end liquidity kept price action tied to broader market tone.
- Investors’ next checkpoint is Pfizer’s Feb. 3 quarterly update and conference call.
Pfizer Inc (NYSE: PFE) shares were down 0.3% at $25 in after-hours trading on Monday, after moving in a tight band during the regular session. The Health Care Select Sector SPDR Fund slipped and large-cap drugmakers traded mixed in late dealings.
The move mattered mainly for timing. With just a handful of sessions left in the year and New Year’s around the corner, many investors are adjusting portfolios rather than reacting to fresh company headlines.
That leaves Pfizer’s stock trading more on positioning and its most recent guidance than on day-to-day news flow. For a high-dividend pharmaceutical name, shifts in risk appetite and interest-rate expectations can sway demand quickly when volumes thin.
U.S. stocks ended lower on Monday as a broad selloff outweighed pockets of strength in defensive sectors, while Treasury yields eased as investors recalibrated expectations for Federal Reserve rate cuts in 2026, Reuters reported. 1
For Pfizer holders, the backdrop is still shaped by management’s outlook for the post-COVID business and the industry’s patent cycle. Big drugmakers face periodic “patent cliffs,” when exclusivity ends and lower-priced generics or biosimilars take share.
Pfizer on Dec. 16 revised full-year 2025 revenue guidance to about $62.0 billion and forecast 2026 revenue of $59.5 billion to $62.5 billion, with adjusted diluted earnings per share of $2.80 to $3.00. “Adjusted” results exclude certain items the company treats as non-recurring; Pfizer also flagged revenue pressure from lower COVID-product sales and “loss of exclusivity,” when patents or regulatory protections expire and competition rises. CEO Albert Bourla said the company is focused on “creating long-term value for our shareholders.” 2
That guidance leaves investors watching two things into 2026: whether Pfizer can offset waning COVID demand and patent losses with newer products, and whether cost actions and R&D spending translate into steadier profit trends.
The next scheduled catalyst is Pfizer’s quarterly update. The company said it will issue its fourth-quarter and full-year 2025 performance report on Feb. 3, before a 10 a.m. EST conference call with analysts. 3
Traders will be listening for any changes to the 2026 revenue bridge the company laid out earlier this month, including updated assumptions on COVID-product sales and timing around products facing competition. Pipeline milestones and spending discipline are likely to be in focus as investors weigh the payoff from recent business development.
Dividend support remains part of the stock’s appeal. Pfizer said on Dec. 12 its board declared a $0.43 first-quarter 2026 dividend, payable March 6, 2026, to shareholders of record on Jan. 23, 2026. 4
Near term, traders are treating $25 as a key round-number level. A break out of the recent narrow range would likely need a clear company-specific catalyst or a sharper move in rates and broader market sentiment.
For now, Pfizer’s stock action reflects a familiar late-December pattern: limited liquidity, cautious risk-taking, and attention shifting to the next earnings print.
